Intravenous (i.v.) phenytoin/fosphenytoin is recommended as the second-line therapy of antiepileptic drugs in patients with status epilepticus (SE). i.v. Levetiracetam is regarded as an effective and safe equivalent with i.v. phenytoin/fosphenytoin. However, i.v. levetiracetam is not covered by public health insurance for SE in most countries. For this study, we performed the real-world practice pattern survey of antiepileptic drugs for status epilepticus using the nationwide inpatient database. We used the Japanese Diagnosis Procedure Combination inpatient database in Japan and identified all cases of emergency admission attributable to status epilepticus from March 2011 through March 2018. We described the patient characteristics and practice pattern of antiepileptic drugs. The analysis conducted for this study examined 31,472 cases. As the second-line therapy, the use of i.v. levetiracetam increased rapidly from 2016; 35% of cases received i.v. levetiracetam in 2017. By contrast, the use of i.v. phenytoin/fosphenytoin decreased from 2016. In-hospital mortality decreased year-by-year. No year-by-year change was observed for deaths within 24 h, length of hospital stay, drug-induced hepatitis, or drug-induced eruption. Although the use of levetiracetam for treatment of SE is not compensated by public health insurance in Japan, i.v. levetiracetam use is increasing dramatically as the second-line SE therapy. We propose that health insurance coverage be extended to include i.v. levetiracetam treatment for SE.
Introduction
Status epilepticus (SE) is an emergency condition in which convulsions persist, and in which recovery is not achieved. This life-threatening condition can cause irreversible cerebral damage. 1) Therefore, it is necessary to stop convulsions promptly and certainly. 2) Potent gamma amino-butyric acid agonists such as lorazepam or diazepam are recommended as first-line drugs. 3, 4) These drugs are short-acting.
Neurol Med Chir (Tokyo) 60, March, 2020 Given this background, the Committee of the American Epilepsy Society guideline introduced i.v. levetiracetam equivalently with i.v. phenytoin/ fosphenytoin as the second-line therapy in the SE treatment algorithm. 14) Levetiracetam was also recommended by expert consensus for use in emergency departments. 15) Nevertheless, i.v. levetiracetam is not included as a treatment for SE by public health insurance or health programs in most European nations. The European Federation of Neurological Societies' guideline refers to levetiracetam by notice of the fact that it is not covered by insurance. 16) Prepared i.v. levetiracetam was introduced into the Japanese market in December 2015. Nevertheless, it has never been covered by national health insurance for treatment of SE.
It is possible that i.v. levetiracetam can be used generally for SE in actual clinical practice. No report exists of nationwide descriptive research on which AEDs are used during the acute phase of SE and which AEDs are finally given for control of epilepsy after SE. For this study, we conducted a real-world practice pattern blot analysis of antiepileptic drugs for status epilepticus using a nationwide inpatient database.
Materials and Methods
The study design was a retrospective observational study using routinely collected data. The Institutional Review Board of The University of Tokyo approved the study. The board waived the requirement for informed consent because of the anonymous characteristics of the data because no information related to individual patients, hospitals, or treating physicians was obtained.
Data source
We used the Japanese Diagnosis Procedure Combination inpatient database, which includes discharge abstracts and administrative claims data for more than 1200 acute-care hospitals and which covers approximately 90% of all tertiarycare emergency hospitals in Japan. The database includes data related to age, sex, body weight, body height, level of consciousness at admission, diagnoses, procedures, prescriptions, and discharge status. The diagnoses are recorded using International Classification of Diseases Tenth Revision (ICD-10) codes and text in Japanese language. Therefore, the diagnostic records are linked to a payment system. For purposes of treatment cost reimbursement, attending physicians are obligated to report objective evidence for their diagnosis. 17) An earlier study of these diagnostic and procedural records established validity of the database, with diagnostic specificity exceeding 96%, and sensitivity of 50-80%. Specificity and sensitivity of procedures each exceeded 90%. 18) 
Study population
We identified all patients with emergency admission due to SE in the database from March 1, 2011 to March 31, 2018. All hospitalized patients diagnosed with SE (ICD-10 code G41) at admission were included in the study. 19) We did not include patients who developed SE after admission. We also excluded patients who were younger than 15 years of age or who were pregnant. When patients were admitted with a diagnosis of SE more than once during the study period, we regarded each admission as an independent case.
Study variables
We collected the following baseline patient characteristics: age, sex, body mass index at admission, Japan Coma Scale status on admission, 20) type of SE, 19) etiology of SE, and comorbidities of mental disorders. 21) Body mass index data were categorized into <18.5, 18.5-24.9, 25.0-29.9, or ≥30.0 kg/m 2 , or missing. Japan Coma Scale status was categorized as alert consciousness, confusion, somnolence, and coma. Japan Coma Scale status has been shown to be well correlated with the Glasgow Coma Scale score. 20) The type of SE was categorized as tonicclonic SE (ICD-10 code: G410), epileptic absence status (G411), complex partial SE (G412), and others or unspecified (G418, G419). 19) The SE etiology was defined using ICD-10 diagnosis code at admission, as below; subarachnoid or intracerebral hemorrhage: I60, I61, I690, I691, cerebral infarction: I63, I693, other cerebral vascular etiologies: G08, G46, I62, I64, I67, I68, I694, I698, Q282, Q283, metabolic etiologies: E035, E05, E100, E101, E110, E111, E120, E121, E130, E131, E140, E141, E15, E161, E162, E222, E232, E51, E52, E53, E61, E70, E71, E72, E73, E74, E75, E76, E77, E80, E83, E870, E871, intoxication: G92, T36, T37, T38, T39, T4, T5, T60, T61, T62, T63, T64, T65, T96, T97, traumatic brain injury: S06, T790, T791, T905, brain neoplasm: C70, C71, C793, D430, D431, D432, D439, D33, inflammation/ immune etiologies: G03, G040, G041, G048, G049, G058, neurodegenerative etiologies: G10, G12, G13, G20, G21, G22, G23, G30, G31, G32, G35, G36, G37, brain infections: G00, G01, G02, G042, G050, G051, G052, G060, G062, G07, other etiologies: G09, G80, G91, G930, G931, G932, G933, G934, G935, G936, G937, G939, G94, I46, P20, P21, Q0, T670, T671, T672, T703, and undetermined: none of above.
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Comorbidities of mental disorders was categorized as organic, including symptomatic, mental disorders (F00-F09), schizophrenia (F20-F29), mood disorders (F30-F39), neurotic, stress-related and somatoform disorders (F40-F48), and other mental disorders (F10-F19, F50-F99). 21) We collected the following clinical outcomes: in-hospital mortality, death within 24 h, length of hospital stay, mechanical ventilation on the day of admission, vasopressor use on the day of admission, drug-induced hepatitis, and drug-induced eruption. ICD-10 codes K71 for complications after admission denoted drug-induced hepatitis. ICD-10 codes L270, L271, L51, or L530 for complications after admission denoted drug-induced eruption.
To investigate the real-world practice patterns of AEDs for SE, we collected the use of i.v. AEDs on the day of admission based on the three clinical phases: 50% glucose, vitamin B1, and diazepam as first-line therapy; phenytoin, fosphenytoin, levetiracetam, and phenobarbital as second-line therapy; and midazolam, propofol, thiopental, and thiamylal as third-line therapy. 14) Because i.v. lorazepam has not been available in Japan, diazepam is often used as the first-line therapy. We also collected the prescriptions of per os (p.o.) AEDs at discharge.
Statistical Analysis
Categorical variables were presented as numbers and percentages. Continuous variables were presented as mean and standard deviation or median and interquartile range. We showed the clinical outcomes, i.v. AEDs on the day of admission, and p.o. AEDs at discharge for each year separated by March 1.
Differences between categorical variables within each
year were analyzed using the Cochrane-Armitage test for trend for proportions. 22) Differences between continuous variables within each year were analyzed using the Jonckheere-Terpstra test for trend. 23) All tests were two-tailed; results for which P <0.05 were inferred as statistically significant. All analyses were conducted using software (STATA/MP 16.0; StataCorp LP, College Station, TX, USA).
Results
During the study period, 40,756 patients were admitted for SE. Of these, we excluded 7418 patients under 15 years old, 44 with pregnancy, and 1822 with planned admission. As a consequence, 31,472 patients were included in the analysis.
The baseline characteristics are shown in Table 1 . Mean (standard deviation) age was 62 (21) years; Figure 1 depicts the trajectory of the breakdown in second-line therapy drugs. Midazolam and propofol as third-line therapy showed no change year-by-year. Clinical outcomes in each second-line drug use on admission is shown in Table 3 .
Discharge prescriptions of p.o. AEDs and the numbers of p.o. AEDs at discharge among patients who received at least one p.o. AED at discharge are shown in Table 4 . The proportion of prescription was the highest for p.o. levetiracetam (50%), followed by sodium valproate (29%) and carbamazepine (22%). The proportion of using p.o. levetiracetam increased year-by-year (P <0.001 for trend). Monotherapy increased year-by-year; combined therapy decreased year-by-year (P <0.001 for trend).
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Discussion
For this study, we investigated the real-world practice patterns of AEDs for SE using a nationwide inpatient database in Japan. Every time new AEDs (such as i.v. fosphenytoin and i.v. levetiracetam) emerged, the second-line therapy for SE changed greatly. Both i.v. and p.o. levetiracetam increased rapidly and were predominantly prescribed in preference to other AEDs in Japan.
To date, i.v. levetiracetam has never been covered by public health insurance or tax in most countries. This study revealed that i.v. levetiracetam was actually used more than i.v. fosphenytoin recently in Japan for patients with SE.
Three randomized controlled trials which compared i.v. levetiracetam and i.v. phenytoin in SE concluded that the efficacy was similar and severe adverse events occurred only in patients with i.v. phenytoin and not observed in patients with i.v. levetiracetam. [10] [11] [12] Side effects of levetiracetam were psychiatric disorders of agitation or somnolence and were not severe even if high-dose levetiracetam was administered. 24) Because of safety, p.o. levetiracetam has been used most frequently as a routine epilepsy treatment in the United States. 25) Our real-world data showed similar results to those obtained from those earlier studies; clinical outcomes and side effects did not worsen year-by-year. Therefore, we propose that public health insurance coverage of i.v. levetiracetam be extended to treatment of SE.
In this study, p.o. levetiracetam at discharge following i.v. levetiracetam on the day of admission was prescribed more than 80% of cases. However, p.o. phenytoin at discharge following i.v. phenytoin/ fosphenytoin on the day of admission was prescribed in only 5.4-6.5% of cases. Same-drug switching was able to facilitate the continuous, stable control of epileptic seizures. This point should be investigated in a future study.
This study has some limitations. First, the diagnosis of SE based on diagnostic codes has not been well validated. Second, the results of trend analyses did not directly demonstrate the association between clinical outcomes and changes of AEDs year-by-year. Third, because the use of i.v. levetiracetam is not compensated by health insurance, some hospitals might not declare the costs of levetiracetam. It is therefore possible that this study has underestimated the use of i.v. levetiracetam.
Conclusion
Although levetiracetam is not recognized as a treatment for SE by the public health insurance system in Japan, i.v. levetiracetam use is increasing dramatically as second-line therapy. We propose that public health insurance coverage of i.v. levetiracetam should be extended to treatment of SE.
